Herbst Kinsky advised Ribbon Biolabs on its EUR 18 million Series A financing round with Hadean Ventures as lead investor and Lansdowne Partners, Helicase Venture IST cube and tecnet equity as existing investors.

Founded in 2018 in Vienna, biotech start-up Ribbon Biolabs aims to redefine the potential of synthetic DNA. The technology targets the growing market need for synthetic DNA of subgenomic size, an essential component for developments in biopharmaceutical research and key to the disruptive potential of synthetic biology.

The company intends to use the new capital to commercialise its DNA synthesis technology, which integrates combinatorial optimisation algorithms to guide the automated enzymatic assembly of DNA.

“Since the beginning of Ribbon we have been supported by Herbst Kinsky’s pristine team. Our journey together has been a very successful one and we look forward to many more inspiring projects and achievements. I would like to give special thanks to the team of Herbst Kinsky for all the hard work and their fast an efficient handling of the transaction of closing our Series A”, says Harold Paul Vladar, CEO at Ribbon Biolabs.

Herbst Kinsky’s team was led by Philipp Kinsky and Carl Walderdorff supported by Christina Bernhart (all Corporate/VC).